BMY vs HCA

Bristol-Myers Squibb's Advanced Deterministic Scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, while the absence of an Altman Z-Score prevents a definitive distress risk assessment. The stock trades below its growth-based intrinsic value of $87.32 at $54.65, suggesting potential undervaluation, yet the high debt/equity ratio and inconsistent earnings performance temper optimism. Strong profitability metrics like 31.57% operating margin and 33.78% ROE are offset by weak recent earnings growth and bearish insider activity. Analysts consensus is a hold with a $56.96 target, implying limited upside, while the 4.59% dividend yield offers income appeal despite an elevated 83.5% payout ratio.

HCA Healthcare trades near its 52-week high with strong price momentum, up 37.9% over the past year and 225.1% over five years, reflecting sustained operational outperformance. The company delivered robust YoY earnings growth of 42.6%, supported by consistent quarterly beats—21 of the last 25 quarters—and accelerating revenue growth at 9.6%. Despite a premium valuation relative to some peers, HCA’s profitability metrics, including a 15.47% operating margin and 12.20% ROA, are industry-leading and justify the multiple. Analysts are aligned with a 'buy' recommendation and a $477.57 target price, implying modest upside, while insider selling remains limited in volume and likely routine.